Imiquimod cream

Imiquimod can induce a variety of cytokines and related products at the local site of medication, thereby producing immunomodulatory and indirect antiviral effects. Imiquimod can effectively induce a variety of cytokines including α-interferon (IFN-α) and tumor necrosis factor (TNF-α) both in vivo and in vitro. In vitro, it can induce human peripheral blood mononuclear cells to produce the following cytokines: α-interferon (IFN-α), tumor necrosis factor α (TNF-α), interleukins (IL-1α, IL-1β, IL-6, 8, 10), colony stimulating factor (C-CSF, GM-CSF) and macrophage inflammatory proteins (MIP-1α, MIP-1β), etc. After topical application of imiquimod cream (0.05μg/cm2) for 1 hour, the concentrations of IFN-α and TNF-α in the skin reached a peak. The two metabolites of imiquimod-S-26704 and S-22770 have similar immune activities. Toxicological study: The maximum concentration of imiquimod cream is 18.3%. It is administered at 1.0g/kg in a local toxicity test on rabbit skin. After continuous administration for one week, except for slight erythema formation, no obvious skin irritation was observed, and no sensitization to guinea pig skin was found. This product has no carcinogenic, mutagenic, or teratogenic toxicity. Skin tolerance tests show that imiquimod is non-irritating to normal human skin.

The active ingredient of this product is imiquimod, and its chemical name is: 1-(2-methylpropyl)-1H-imidazo[4,5-C]quinolin-4-amine.

This product is a white cream.

Genital and perianal warts.

1. Take the medicine before going to bed 3 times a week (Monday, Wednesday, Friday or Tuesday, Thursday, Saturday). Use the medicine reasonably under the doctor's prescription to maximize the efficacy of this product. It is recommended to wash your hands before and after taking the medicine. Avoid overdosing on this product. 2. Apply a thin layer of the ointment evenly to the wart affected area, gently massage until the medicine is completely absorbed, and keep it for 6-10 hours. Do not seal the medication site. Do not take a bath during the 6-10 hours after applying the ointment. 3. After 6 to 10 hours, wash the medicine off the wart affected area with clean water and neutral soap. 4. The patient should continue to use the ointment until the wart is completely removed. The wart is removed in 2-4 weeks at the fastest, generally in 8-12 weeks, and no more than 16 weeks at most. 5. If there is mild erythema locally after taking the medicine, it is not necessary to stop the medicine and continue to use it; if the patient feels general discomfort or has a more obvious local skin reaction (such as more obvious edema, erosion, pain, etc.), the drug should be discontinued several times and continued after the reaction is alleviated.

Most patients do not have any adverse reactions during the treatment. After several doses of medication, the adverse reactions that may occur clinically are mostly mild or moderate local skin inflammation reactions, such as erythema, edema, erosion, ulcer, desquamation, burning, pain, itching, etc. on the local skin; occasionally short-term low fever, the above symptoms can be quickly recovered after stopping the medication. If the reaction is mild, you can continue to use the medication; if the reaction is serious, you should stop the medication in time and seek medical attention. According to foreign data reports, the adverse reactions that may be related to imiquimod cream include: discomfort at the medication site; reactions at the wart site (burning, pigmentation, inflammation, itching, pain, rash, sensitivity, ulcer, tingling, tenderness); reactions at the distal site (bleeding, burning, itching, pain, tenderness); systemic reactions: fatigue, fever, flu-like symptoms; central and peripheral nervous system: headache; gastrointestinal system: diarrhea; musculoskeletal system: myalgia.

Not yet known.

Precautions for children: The safety and efficacy of this product in patients under 18 years of age have not been established. Precautions for pregnancy and lactation: 1. This product is not recommended for pregnant women. 2. It is not known whether the drug is secreted in breast milk after topical application of imiquimod. This product is not recommended for lactating women. Precautions for the elderly: The safety and efficacy data of this product for elderly patients have not been established.

This experiment has not been conducted and there are no reliable references.

Protect from light and store in sealed container at 25°C.

3g:0.15g

24 months.

Hubei KEYI Pharmaceutical Industry Co., Ltd.

• Founded in:

  1997-05-23

• Address:

  No. 8, Huanglongshan South Road, East Lake New Technology Development Zone, Wuhan

• Tax NO.:

  91420000726103295U

• Registered Funds:

  34.750206 million yuan

• Email:

  Log in to view